Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.31 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.31 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16247707 | 0.85 | LGALS3 (0.39) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL14885752 | 0.74 | MMP9 (0.31) | CD69LGALS3ALDH1A1 | |
| SCHEMBL13815458 | 0.72 | LGALS3 (0.34) | CD69LGALS3LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL17970992 | 0.70 | CD69 (0.39) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL17212844 | 0.69 | LGALS3 (0.46) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL20122284 | 0.68 | LGALS3 (0.52) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL16521135 | 0.67 | LGALS3 (0.35) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL15274901 | 0.66 | LGALS3 (0.45) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL16659352 | 0.66 | LGALS3 (0.45) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B | |
| SCHEMBL18589697 | 0.66 | LGALS3 (0.45) | CD69MAPK1LGALS3LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102561-A1 | Stabalized Glycosaminoglycan Preparations and Related Methods | S.K. PHARMACEUTICALS (US) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102561-A1 | Stabalized Glycosaminoglycan Preparations and Related Methods | CD44, PLOD3, EGLN3 | CD69 1829/4885MAPK1 2491/4885LGALS3 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.